<unk>  is a CD22-directed antibody-drug conjugate (ADC) that is FDA approved for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include thrombocytopenia, neutropenia, infection, anemia, leukopenia, fatigue, hemorrhage, pyrexia, nausea, headache, febrile neutropenia, transaminases increased, abdominal pain, gamma-glutamyltransferase increased, and hyperbilirubinemia.
Inotuzumab ozogamicin
Ranibizumab
Dabrafenib mesylate
Gemtuzumab ozogamicin
Pazopanib hydrochloride
Bevacizumab
Ruxolitinib
Erdafitinib